Bristol-Myers Squibb Company (NYSE: BMY) is now fully own MyoKardia after it has finalized the buying process. BMY has bought MyoKardia Inc. in an all-cash deal for nearly $13.1 billion. After this deal, Bristol-Myers will get mavacamten which is the cardiovascular drug used
